BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:11 PM
 | 
Sep 06, 2012
 |  BC Extra  |  Clinical News

Lilly's Alimta misses maintenance therapy endpoint in NSCLC

Eli Lilly and Co. (NYSE:LLY) said maintenance therapy with Alimta pemetrexed plus Avastin bevacizumab missed the primary endpoint of improving median overall survival (OS) vs. Avastin alone in the Phase III POINTBREAK trial in stage IIIb/IV non-squamous...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >